Renewable Energy PPA: Emcure Pharmaceuticals Strengthens Sustainability with Major Solar Power Agreement

published on 30 July 2024
28-1-d0x5t

Emcure Pharmaceuticals has taken a bold step towards sustainability by signing a 22.78 MWp DC Solar Power Purchase Agreement (PPA) with Sunsure Energy. This significant move not only boosts Emcure's green energy credentials but also sets a new standard for the pharmaceutical industry.

A Significant Leap Towards Green Energy

Emcure Pharmaceuticals, along with its subsidiary Gennova Biopharmaceuticals Limited, has committed to a massive solar power initiative. By partnering with Sunsure Energy, Emcure will receive approximately 36 million units of renewable energy annually, meeting around 67% of their power needs for their Pune manufacturing facilities. This green energy transition will significantly reduce their carbon footprint, offsetting nearly 29,765.71 metric tons of CO2 emissions each year. Such a commitment showcases Emcure's dedication to integrating sustainability into its core operations.

Strategic Partnerships and Stake Acquisition

As part of the solar power agreement, Emcure and Gennova will also acquire a stake in Sunsure Solarpark Twelve Private Limited. This strategic move facilitates their solar power purchase under a group captive scheme, aligning with the Electricity Act, 2023. The power will be supplied from Sunsure's 150 MWp DC solar plant in Solapur, Maharashtra. This partnership not only emphasizes Emcure’s proactive approach to sustainability but also highlights the importance of collaborative efforts in advancing renewable energy initiatives.

Comprehensive Environmental Commitment

Emcure Pharmaceuticals is renowned for its holistic approach to environmental sustainability. Beyond this solar power agreement, Emcure implements numerous green initiatives across its operations. These include energy-efficient systems, advanced waste management, pollution control measures, and rainwater harvesting. Their R&D efforts focus on solvent recycling and recovery, and their manufacturing plants are equipped with Zero Liquid Discharge systems and Effluent Treatment Plants, ensuring 100% waste treatment. This comprehensive commitment underscores Emcure’s role in promoting sustainable development and environmental protection within the pharmaceutical sector.

Conclusion

Emcure Pharmaceuticals' new solar power agreement with Sunsure Energy marks a pivotal step in their sustainability journey. By significantly reducing their carbon footprint and integrating renewable energy into their operations, Emcure is setting a new benchmark for the pharmaceutical industry. 

The above analysis is proprietary to Enerdatics’ energy analytics team, based on the current understanding of the available data. The information is subject to change and should not be taken to constitute professional advice or a recommendation.

Click to know more about Enerdatics' Renewable Energy M&A, Finance, PPA, and Projects databases.

Read more